Regeneron’s cemdisiran for AChR-antibody positive and argenx’s efgartigimod for AChR-antibody negative generalized myasthenia ...

Inside Gilead Sciences, colleagues often describe Varun Sharma as the strategist who can map a launch plan end to end, and ...

Some of the state’s largest – and smallest – public schools will be bursting at the seams next year, as parents seek to enrol ...

India's school enrolment dropped by 1.11 million in 2024-25, mainly in early education, due to declining birth rates and a shift to private schools.

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...

Chronic rhinosinusitis is an inflammatory disease involving the sinonasal cavity, affecting 5–12% of the general population.1 The diagnosis of chronic rhinosinusitis, which includes chronic ...

Oral therapy Relyvrio, which Amylyx is again referring to as AMX0035, was tested in progressive supranuclear palsy (PSP), a ...

Lilly’s investigational drug met primary and key secondary endpoints in ATTAIN-2, showing significant weight loss and reduced A1c in people with obesity or overweight and type 2 diabetes.

Regeneron (REGN) stock and Alnylam Pharma (ALNY) stock are in focus as their RNA therapy cemdisiran succeeds in Phase 3 trial for myasthenia gravis. Read more here.

We take a closer look at an ambitious survey of pupil attitudes that seeks to pinpoint the Year 7 school engagement ...

Eli Lilly’s trial testing its obesity pill found that the highest dose of the drug lowered participants weight by 10.5% ...